Mediclinic International Plc

Public consensus   -   Last updated 23/07/21

Reporting currency: GBP
Reporting unit: Absolute
 
NO. OF
FORECASTS
FY23
CONSENSUS
23/07/21
FY23
MIN
FY23
MAX
Hirslanden (CHF'm) - Adjusted
Revenue
9
1,863
1,828
1,921
EBITDA
9
303
273
329
EBITDA margin (%)
9
16.3
14.9
17.1
Average FX rate GBP/CHF
9
1.26
1.19
1.41
Southern Africa (ZAR'm) - Adjusted
Revenue
9
18,504
17,569
19,828
EBITDA
9
3,764
3,416
4,145
EBITDA margin (%)
9
20.3
19.0
21.8
Average FX rate GBP/ZAR
9
20.58
19.19
21.30
Middle East (AED'm) - Adjusted
Revenue
9
4,120
3,888
4,239
EBITDA
9
636
564
686
EBITDA margin (%)
9
15.4
14.5
16.2
Average FX rate GBP/AED
9
5.08
4.80
5.40
Adjusted Group (GBP'm)
Revenue
9
3,187
3,083
3,276
EBITDA
9
547
516
583
EBITDA margin (%)
9
17.2
16.4
17.8
D&A
9
(223)
(238)
(203)
Operating profit
9
324
295
380
Net finance cost
9
(68)
(101)
(49)
Share of profit of equity accounted investment
6
6
3
9
Earnings (equity holders)
9
188
171
232
Earnings per share (pence)
9
25.4
22.7
31.4
Dividend per share (pence)
9
6.7
4.2
9.1
Net Debt
9
1,701
888
2,078
Net cash generated from operating activities
8
406
377
436
Total Group Capex
9
210
161
252

Disclaimer

Mediclinic International plc (“Mediclinic”) does not endorse or adopt any of the consensus estimates expressed in this report. The report represents the views of analysts from which the consensus estimates are derived. Mediclinic will not provide any commentary on the consensus or answer questions on it. The circulation of the consensus by Mediclinic is not mandatory and Mediclinic may amend its practice on this at any time.